Markets:

Overview

News

Currencies

International

Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

20.84 -0.66 (-3.07%)

Streaming Delayed Price Updated: 10:31 AM EDT, Jul 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed ↗

August 11, 2022

Via Benzinga

Adaptive Biotechnologies: Q2 Earnings Insights ↗

August 03, 2022

Adaptive Biotechnologies (NASDAQ:ADPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Outlook For Adaptive Biotechnologies ↗

August 02, 2022

Adaptive Biotechnologies (NASDAQ:ADPT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Why Adaptive Biotechnologies Shares Are Rising ↗

June 15, 2022

Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares are trading higher by 12.58% to $7.25 after the company launched T-Detect Lyme, to help diagnose early lyme disease.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗

June 03, 2022

Via Benzinga

Adaptive Biotechnologies Clocks 26% Jump In Q4 Revenues ↗

February 16, 2022

Adaptive Biotechnologies Corp (NASDAQ: ADPT)

Via Benzinga

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed ↗

May 23, 2022

Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $38.62 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 2.35%, resulting in a loss of $62.80...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 23, 2022

Gainers Creative Medical Tech (NASDAQ:CELZ) shares rose 78.8% to $3.04 during Wednesday's pre-market session. The market value of their outstanding shares is at $19.2...

Via Benzinga

Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO ↗

March 09, 2022

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) will be organized around two distinct business areas - Minimal Residual Disease (MRD) and Immune Medicine. Adaptive's...

Via Benzinga

Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed ↗

February 16, 2022

Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $37.93 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 9.57%, resulting in a loss of $61.36...

Via Benzinga

Recap: Adaptive Biotechnologies Q4 Earnings ↗

February 15, 2022

Adaptive Biotechnologies (NASDAQ:ADPT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗

August 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...

Via Benzinga

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗

August 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Unusual Options Activity Insight: Adaptive Biotechnologies ↗

August 04, 2021

Adaptive Biotechnologies (NASDAQ:ADPT) shares experienced ...

Via Benzinga

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics ↗

February 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...

Via Benzinga

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗

February 13, 2022

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...

Via Benzinga

12 Publicly Traded Companies On Fast Company's 'Next Big Things In Tech' List ↗

December 01, 2021

Real-world problem solvers are highlighted in the inaugural “Next Big Things In Tech” list by Fast Company. The list included 65 honorees from big companies to start-...

Via Benzinga

Earnings Scheduled For February 15, 2022 ↗

February 15, 2022

Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion.

Via Benzinga

Cathie Wood Goes Bargain Shopping -- 3 Troubled Stocks She Just Bought ↗

November 29, 2021

The internet's favorite stock picker has been very busy.

Via The Motley Fool

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗

November 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...

Via Benzinga

Adaptive Biotechnologies Corporation (ADPT) Q3 2021 Earnings Call Transcript ↗

November 04, 2021

ADPT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs ↗

October 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...

Via Benzinga

Return on Capital Employed Insights for Adaptive Biotechnologies ↗

August 20, 2021

After pulling data from Benzinga Pro it seems like during Q2, Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $38.51 million. However, earnings decreased 20.55%,...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck ↗

August 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Adaptive Biotechnologies Corporation (ADPT) Q2 2021 Earnings Call Transcript ↗

August 05, 2021

ADPT earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

This Explosive Biotech Is Taking On a Huge New Market ↗

June 30, 2021

Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.

Via The Motley Fool

Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares ↗

May 12, 2021

Cathie Wood-led Ark Investment Management on Wednesday snapped up 2.07 million shares, worth about $39 million, in Palantir Technologies Inc (NYSE: PLTR), on a day the...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.